HENDERSON, Nev.--(BUSINESS WIRE)--Apr 17, 2012-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the first quarter 2012 financial results, provide an update on the Company's business, and discuss expectations for the future.

Conference Call Thursday, April 26, 2012 @ 1:30 p.m. Eastern/10:30 a.m. Pacific Domestic: (877) 837-3910, Conference ID? 72508257 International:(973) 796-5077, Conference ID? 72508257 For interested individuals unable to join the call, a replay will be available from April 26, 2012 @ 4:30 p.m. ET/1:30 p.m. PT through May 9, 2012 until 11:59 p.m. ET/8:59 p.m. PT.

Domestic Replay Dial-In ?: (855) 859-2056, Conference ID? 72508257 International Replay Dial-In ?:(404) 537-3406, Conference ID? 72508257 This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: on April 26, 2012 at 1:30 p.m. Eastern/10:30 a.m. Pacific.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biotechnology company with a primary focus in oncology and hematology. Spectrum's strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial drug products. Spectrum has aggressive business development and commercial operation teams that support a robust drug development program encompassing clinical development, medical research, regulatory affairs, biostatistics and data management. Spectrum also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit Spectrum's website at

Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially.

These statements are based on management's current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees, around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new applications to the FDA may not receive approval, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.(R) is a registered trademark of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE(TM) and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

5/8 2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

CONTACT: Spectrum Pharmaceuticals, Inc.

Shiv Kapoor Vice President, Strategic Planning & Investor Relations 702-835-6300 KEYWORD: UNITED STATES NORTH AMERICA NEVADA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL SOURCE: Spectrum Pharmaceuticals, Inc.

Copyright Business Wire 2012 PUB: 04/17/2012 07:00 AM/DISC: 04/17/2012 07:00 AM